Physician profile
Debra Bugbee
NPI 1508181959
$3,228.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $1,016 · 2023: $884 · 2024: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $530.01 | 2021-2024 | Repatha |
| Abbott Laboratories | $409.65 | 2021-2024 | Mitraclip, Assurity, Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $300.37 | 2021-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $278.06 | 2021-2024 | |
| Glaxosmithkline, LLC. | $229.12 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $205.30 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $200.76 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $112.08 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.82 | 2021-2023 | Jardiance |
| United Therapeutics Corporation | $101.49 | 2022-2024 | Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals Lp | $98.37 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $84.69 | 2021-2024 | Verquvo, Recarbrio, Dificid |
| Mylan Specialty L.P. | $83.43 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $81.44 | 2022 | |
| Biosense Webster, INC. | $74.39 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $64.22 | 2023-2024 | |
| Heartflow, INC. | $44.46 | 2021 | |
| Alnylam Pharmaceuticals INC. | $44.43 | 2022-2023 | Onpattro |
| Abbvie INC. | $43.07 | 2022-2023 | |
| Daiichi Sankyo INC. | $29.33 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $28.91 | 2022 | |
| Boston Scientific Corporation | $24.82 | 2022 | |
| Baxter Healthcare | $19.50 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $17.78 | 2022 | |
| Philips North America LLC | $15.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Bugbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.